Hyderabad-based GCBC Vaccines has received WHO reapproval for its oral cholera vaccine, Shanchol, originally developed by Shantha Biotechnics. The move revives India’s role in ensuring global vaccine supply and supports public health efforts against recurring cholera outbreaks.

Hyderabad: Reinforcing its title as the vaccine capital of India, a major pharma company from Hyderabad is set to re-energise the global supply of the life-saving oral cholera vaccine.

Shanchol, the oral cholera vaccine originally developed by Hyderabad-based Shantha Biotechnics, has received prequalification from the World Health Organization (WHO), enabling global procurement agencies such as UNICEF, Gavi and PAHO to source the vaccine for use in countries where cholera remains a major public health challenge

See Full Page